[go: up one dir, main page]

WO2000031238A3 - Methods and reagents for increasing proliferative capacity and preventing replicative senescence - Google Patents

Methods and reagents for increasing proliferative capacity and preventing replicative senescence Download PDF

Info

Publication number
WO2000031238A3
WO2000031238A3 PCT/US1999/027907 US9927907W WO0031238A3 WO 2000031238 A3 WO2000031238 A3 WO 2000031238A3 US 9927907 W US9927907 W US 9927907W WO 0031238 A3 WO0031238 A3 WO 0031238A3
Authority
WO
WIPO (PCT)
Prior art keywords
reagents
methods
proliferative capacity
replicative senescence
increasing proliferative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/027907
Other languages
French (fr)
Other versions
WO2000031238A2 (en
Inventor
Gregory J Hannon
David H Beach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENETICA Inc
Original Assignee
GENETICA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENETICA Inc filed Critical GENETICA Inc
Priority to JP2000584049A priority Critical patent/JP2002530436A/en
Priority to IL14332899A priority patent/IL143328A0/en
Priority to AU21566/00A priority patent/AU2156600A/en
Priority to CA002352486A priority patent/CA2352486A1/en
Priority to EP99965890A priority patent/EP1133552A2/en
Publication of WO2000031238A2 publication Critical patent/WO2000031238A2/en
Publication of WO2000031238A3 publication Critical patent/WO2000031238A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to methods and reagents for extending the life-span, e.g. the number of mitotic divisions, of a cell. In general, the subject method relies on the activation of a telomerase activity and inhibition of one or both of an Rb/p16 pathway or a p53 pathway.
PCT/US1999/027907 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence Ceased WO2000031238A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000584049A JP2002530436A (en) 1998-11-25 1999-11-24 Method and reagent for enhancing proliferation ability and preventing replication senescence
IL14332899A IL143328A0 (en) 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
AU21566/00A AU2156600A (en) 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
CA002352486A CA2352486A1 (en) 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence
EP99965890A EP1133552A2 (en) 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10989198P 1998-11-25 1998-11-25
US12054999P 1999-02-17 1999-02-17
US60/120,549 1999-02-17
US60/109.891 1999-02-17

Publications (2)

Publication Number Publication Date
WO2000031238A2 WO2000031238A2 (en) 2000-06-02
WO2000031238A3 true WO2000031238A3 (en) 2000-11-09

Family

ID=26807479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027907 Ceased WO2000031238A2 (en) 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence

Country Status (6)

Country Link
EP (1) EP1133552A2 (en)
JP (1) JP2002530436A (en)
AU (1) AU2156600A (en)
CA (1) CA2352486A1 (en)
IL (1) IL143328A0 (en)
WO (1) WO2000031238A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
HK1042251B (en) 1999-01-13 2012-07-20 Bayer Healthcare Llc Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
EP1170378A1 (en) * 2000-06-26 2002-01-09 Boehringer Ingelheim International GmbH Method for monitoring the effect of cancer therapies
DE10054974A1 (en) * 2000-11-06 2002-06-06 Epigenomics Ag Diagnosis of diseases associated with Cdk4
EP1370132A2 (en) 2001-03-21 2003-12-17 Geron Corporation Use of telomerase reverse transcriptase to create homozygous knockout animals
AU2002342613A1 (en) 2001-05-09 2002-11-25 Geron Corporation Treatment for wounds
WO2003066839A1 (en) * 2002-02-05 2003-08-14 Rappaport Family Institute For Research In The Medical Sciences Lineage committed stem cells selected for telomerase promoter activity
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
CA2517285A1 (en) * 2003-02-26 2004-09-10 Japan Science And Technology Agency Transcriptional factor inducing apoptosis in cancer cell
PT1626714E (en) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp DIARILURIES FOR PDGFR MEDICATED DISEASES
HRP20180330T1 (en) 2003-06-23 2018-04-20 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
US9248088B2 (en) 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
DE602004010407T2 (en) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING
MX2007003795A (en) * 2004-09-28 2007-07-11 Quark Biotech Inc Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases.
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
JP2006325444A (en) * 2005-05-24 2006-12-07 Toyobo Co Ltd Cell growth medium
WO2007056423A1 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Methods and compositions for modulation of stem cell aging
JP5372769B2 (en) 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド Method for treating human disease associated with increased amount of deoxyribonucleic acid in the extracellular space of tissue and pharmaceutical formulation for performing the method
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
ES2661310T3 (en) 2009-03-09 2018-03-28 Bioatla, Llc Mirac proteins
CN102448308B (en) 2009-05-18 2014-08-06 吉隆公司 Compositions and methods for increasing telomerase activity
PL2536830T3 (en) 2010-02-16 2020-02-28 Ultimovacs As Polypeptides
GB201202228D0 (en) * 2012-02-08 2012-03-28 Queen Mary & Westfield College Reversal of replicative senescence
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
CA3047140A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Constructs for expression of therapeutic proteins in target cells
JP2021510539A (en) 2018-01-16 2021-04-30 シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Treatment of diseases by liver expression of enzymes with deoxyribonuclease (DNase) activity
WO2019166702A1 (en) 2018-02-28 2019-09-06 Hagalife Use of a flash irradiation method to increase longevity and/or to delay the effects of ageing in mammals
JP7592493B2 (en) 2018-04-18 2024-12-02 オイシン バイオテクノロジーズ，インク． Fusogenic lipid nanoparticles and methods of making and using the same for target cell specific production of therapeutic proteins and for treatment of target cell associated diseases, illnesses or disorders - Patents.com
CN113774020B (en) * 2021-08-24 2023-04-14 河北朋和生物科技有限公司 A method for constructing adipose-derived mesenchymal stem cell bank

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537008A1 (en) * 1991-10-11 1993-04-14 E.R. SQUIBB & SONS, INC. Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes
EP0618221A2 (en) * 1993-04-02 1994-10-05 Bristol-Myers Squibb Company Heterocyclic inhibitors of farnesyl protein transferase
WO1996012820A1 (en) * 1994-10-24 1996-05-02 Cold Spring Harbor Laboratory INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO
US5624936A (en) * 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
WO1999035243A2 (en) * 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
WO1999042578A2 (en) * 1998-01-30 1999-08-26 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537008A1 (en) * 1991-10-11 1993-04-14 E.R. SQUIBB & SONS, INC. Use of biphosphonates for the manufacture of a medicament for blocking neoplastic transformation of cells induced by ras oncogenes
EP0618221A2 (en) * 1993-04-02 1994-10-05 Bristol-Myers Squibb Company Heterocyclic inhibitors of farnesyl protein transferase
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1996012820A1 (en) * 1994-10-24 1996-05-02 Cold Spring Harbor Laboratory INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO
US5624936A (en) * 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
WO1999035243A2 (en) * 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
WO1999042578A2 (en) * 1998-01-30 1999-08-26 Cold Spring Harbor Laboratory Modulation of cell proliferation, methods and reagents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
EILEEN M. ROGAN ET AL: "Alterations in p53 and p16INK4a Expression and Telomere Length during spontaneous Immortalization of Li-Fraumeni Syndrome Fibroblasts", MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 9, September 1995 (1995-09-01), pages 4745 - 4753, XP002142068 *
G. I. SHAPIRO ET AL: "p16INK14a Participates in a G1 arrest Checkpoint in Response to DNA Damage", MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 1, January 1998 (1998-01-01), pages 378 - 387, XP002142070 *
M KUBBUTAT ET AL: "Regulation of p53 stability by mdm2", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 387, 15 May 1997 (1997-05-15), pages 299 - 303, XP002075660, ISSN: 0028-0836 *
M. MEYYAPPAN ET AL: "Increased Expression of Cyclin D2 during Multiple States of Growth Arrest in Primary and Established Cells", MOLECULAR AND CELLULAR BIOLOGY, vol. 18, no. 6, June 1998 (1998-06-01), pages 3163 - 3172, XP002142069 *
T. KIYONO ET AL: "both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells", NATURE, vol. 396, 5 November 1998 (1998-11-05), pages 84 - 88, XP002142067 *
VAZIRI H ET AL: "ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase", EMBO JOURNAL,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 16, no. 19, 1 October 1997 (1997-10-01), pages 6018 - 6033, XP002118901, ISSN: 0261-4189 *
XU H -J ET AL: "REEXPRESSION OF THE RETINOBLASTOMA PROTEIN IN TUMOR CELLS INDUCES SENESCENCE AND TELOMERASE INHIBITION", ONCOGENE,GB,BASINGSTOKE, HANTS, vol. 15, no. 21, 1 January 1997 (1997-01-01), pages 2589 - 2596, XP002068735, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
CA2352486A1 (en) 2000-06-02
IL143328A0 (en) 2002-04-21
WO2000031238A2 (en) 2000-06-02
EP1133552A2 (en) 2001-09-19
AU2156600A (en) 2000-06-13
JP2002530436A (en) 2002-09-17

Similar Documents

Publication Publication Date Title
WO2000031238A3 (en) Methods and reagents for increasing proliferative capacity and preventing replicative senescence
WO1999035243A3 (en) Extension of cellular lifespan, methods and reagents
DE3063025D1 (en) Compositions, methods and elements for detecting or assaying peroxidatively active substances
AU1804300A (en) Materials for polishing liquid for metal, polishing liquid for metal, method forpreparation thereof and polishing method using the same
AU7349198A (en) Nucleic acid probes for the detection and identification of fungi
AU3704200A (en) Viability assay for sporocyst-forming protozoa
WO2001085550A3 (en) Specimen plate lid and method of using
AU3564199A (en) Multi-use razor
WO1999054286A3 (en) Btk inhibitors and methods for their identification and use
AU2001288750A1 (en) Particle or cell analyzer and method
EP1024544A3 (en) Anode material for lithium secondary battery, lithium secondary battery using said anode material, and method for charging of said secondary battery
WO2002004488A3 (en) Nucleic acid binding polypeptides
WO2003048300A3 (en) Methods of identifying cellular target molecules
AU3765299A (en) Catalyzed hydrocarbon trap and method using the same
EP1065213A3 (en) HCV polymerase suitable for crystal structure analysis and method for using the enzyme
AU2002246792A1 (en) Identification of individual cells during kinetic assays
ZA972078B (en) Method and media for enhancing viability, maturation, and cryopreservation of cells.
AU6826900A (en) Method of determining the activity of 1-deoxy-d-xylulose-5-phosphate reductoisomerase and 1-deoxy-d-xylulose-5-phosphate synthase
WO2001066144A3 (en) Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
WO2000056924A3 (en) Genomic sequence of the purh gene and purh-related biallelic markers
AU2001279525A1 (en) Secretase/sheddase with asp-ase activity on the beta-site app-cleaving enzyme (bace, asp2, memepsin 2)
AU1068900A (en) Detecting the expression of the desc1 gene in squamous cell carcinoma
AU2973799A (en) Methods for cleaving single-stranded and double-stranded dna substrates with nucleotide integrase
EP1300473A4 (en) Method of detecting nucleotide polymorphism
IL137197A0 (en) Modulation of cell proliferation, methods and reagents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 143328

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2352486

Country of ref document: CA

Ref country code: CA

Ref document number: 2352486

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 584049

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 21566/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999965890

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999965890

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09936035

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999965890

Country of ref document: EP